World's Best Scientists 2026 revealed!
Gabriella Fontanini

Gabriella Fontanini

D-Index & Metrics

Medicine

D-Index
80
Citations
23476
World Ranking
17105
National Ranking
689

Overview

Gabriella Fontanini is affiliated with the University of Pisa in Italy and has a substantial body of work within the fields of Medicine and Biochemistry, Genetics and Molecular Biology. Their research primarily focuses on oncology, pulmonary and respiratory medicine, pathology and forensic medicine, cancer research, and molecular biology.

Their main research topics include colorectal cancer treatments and studies, cancer genomics and diagnostics, genetic factors in colorectal cancer, lung cancer treatments and mutations, cancer immunotherapy and biomarkers, hepatocellular carcinoma treatment and prognosis, as well as occupational and environmental lung diseases.

Recent significant publications by Gabriella Fontanini include:

  • Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial, 2020, The Lancet Oncology
  • Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial, 2022, The Lancet Oncology
  • Next Generation Sequencing for Gene Fusion Analysis in Lung Cancer: A Literature Review, 2020, Diagnostics
  • Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO, 2022, Journal of Clinical Oncology
  • Global impact of the COVID-19 pandemic on cytopathology practice: Results from an international survey of laboratories in 23 countries, 2020, Cancer Cytopathology

Frequent co-authors in Gabriella Fontanini's publications include:

  • Chiara Cremolini
  • Greta Alì
  • Mirella Giordano
  • Sara Lonardi
  • Clara Ugolini

Their work is regularly published in several scientific journals, with repeated contributions to:

  • Diagnostics
  • Journal of Clinical Oncology
  • Annals of Oncology
  • European Journal of Cancer
  • Frontiers in Oncology

Gabriella Fontanini's research contributions span a range of complex medical and biological topics that intersect oncology and molecular biology fields, with a detailed focus on colorectal and lung cancer treatment approaches as well as diagnostics. Their collaboration with prominent co-authors and presence in high-impact journals underscores ongoing engagement within the scientific community in cancer research and related medical disciplines.

Best Publications

  • Relation of neovascularisation to metastasis of non-small-cell lung cancer.

    P Macchiarini;G Fontanini;F Squartini;C.A Angeletti

  • FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study

    Chiara Cremolini;Fotios Loupakis;Carlotta Antoniotti;Cristiana Lupi

  • Inhibition of Growth Factor Production and Angiogenesis in Human Cancer Cells by ZD1839 (Iressa), a Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor,

    Fortunato Ciardiello;Rosa Caputo;Roberto Bianco;Vincenzo Damiano

  • ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.

    Francesca Carlomagno;Donata Vitagliano;Teresa Guida;Fortunato Ciardiello

  • KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer

    F Loupakis;A Ruzzo;C Cremolini;B Vincenzi

  • PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients.

    A D'Incecco;M. Andreozzi;V. Ludovini;E. Rossi

  • Antitumor Effects of ZD6474, a Small Molecule Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, with Additional Activity against Epidermal Growth Factor Receptor Tyrosine Kinase

    Fortunato Ciardiello;Rosa Caputo;Vincenzo Damiano;Roberta Caputo

  • Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma.

    G Fontanini;S Vignati;L Boldrini;S Chinè

  • Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival.

    G Fontanini;M De Laurentiis;S Vignati;S Chinè

  • Angiogenesis as a Prognostic Indicator of Survival in Non-Small-Cell Lung Carcinoma: a Prospective Study

    Gabriella Fontanini;Marco Lucchi;S Vignati;Alfredo Mussi

  • Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa)

    Cataldo Bianco;Giampaolo Tortora;Roberto Bianco;Roberta Caputo

  • Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial

    Gianluca Masi;Fotios Loupakis;Lisa Salvatore;Lorenzo Fornaro

  • Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer.

    Gabriella Fontanini;S Vignati;D Bigini;Alfredo Mussi

  • Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

    Chiara Cremolini;Carlotta Antoniotti;Daniele Rossini;Sara Lonardi

  • Mechanical prevention of distal embolization during primary angioplasty: safety, feasibility, and impact on myocardial reperfusion.

    Ugo Limbruno;Andrea Micheli;Marco De Carlo;Giovanni Amoroso

  • Microvessel count predicts metastatic disease and survival in non‐small cell lung cancer

    Gabriella Fontanini;Daniela Bigini;Silvana Vignati;Fulvio Basolo

  • A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors.

    Iacopo Petrini;Paul S. Meltzer;In Kyu Kim;Marco Lucchi

  • Lung neuroendocrine tumours: Deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D

    Michele Simbolo;Andrea Mafficini;Katarzyna O Sikora;Matteo Fassan

  • FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer

    F. Loupakis;C. Cremolini;L. Salvatore;G. Masi

  • N-ras Mutation in Poorly Differentiated Thyroid Carcinomas: Correlation with Bone Metastases and Inverse Correlation to Thyroglobulin Expression

    Fulvio Basolo;Fioravante Pisaturo;Luca E. Pollina;Gabriella Fontanini

Frequent Co-Authors

Fulvio Basolo
Fulvio Basolo University of Pisa
Alfredo Falcone
Alfredo Falcone University of Pisa
Fotios Loupakis
Fotios Loupakis Istituto Oncologico Veneto
Sara Lonardi
Sara Lonardi Istituto Oncologico Veneto
Fortunato Ciardiello
Fortunato Ciardiello University of Campania "Luigi Vanvitelli"
Giampaolo Tortora
Giampaolo Tortora University of Verona
Paolo Miccoli
Paolo Miccoli University of Pisa
Federico Cappuzzo
Federico Cappuzzo Azienda Unità Sanitaria Locale Della Romagna
Romano Danesi
Romano Danesi University of Pisa
Antonio Toniolo
Antonio Toniolo University of Insubria

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering Medicine in the USA opens doors to a variety of allied health and administrative careers. Many students are exploring flexible degrees through online platforms, making it easier to balance study and other commitments. Whether you want to advance in clinical practice or healthcare management, there are online options to match your interests and timeframe.

Aspiring nurse practitioners can benefit from online dnp programs that allow for doctoral-level advancement without disrupting your current role. Those seeking a quicker entry into healthcare may consider completing a fast track medical lpn course, which helps launch a practical nursing career in less time.

Specialized programs like the shortest online pmhnp programs offer an accelerated pathway towards becoming a psychiatric mental health nurse practitioner. If you’re more interested in the business and leadership side of healthcare, an online healthcare administration degree can prepare you for management roles in hospitals, clinics, and related organizations.

These related degrees and faster career tracks offer flexible opportunities for anyone looking to enter or advance within the healthcare sector.

Best Scientists Citing Gabriella Fontanini

Trending Scientists

Recently Published Articles